On the Record · Envista Holdings
Envista Holdings acquisitions, on the record
The businesses Envista Holdings bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Osteogenics Biomedical Inc., Allotech LLC and OBI Biologics, Inc. (together "Osteogenics")Word for word“On July 5, 2022, we acquired all of the equity of Osteogenics Biomedical Inc., Allotech LLC and OBI Biologics, Inc. (together "Osteogenics").” 10-K for 2023 | acquisition | On July 5, 2022 | — |
Carestream Dental Technology Parent Limited's ("Carestream Dental") intraoral scanner business (the "Intraoral Scanner Business")Word for word“On April 20, 2022, we completed the acquisition of Carestream Dental Technology Parent Limited's ("Carestream Dental") intraoral scanner business (the "Intraoral Scanner Business").” 10-K for 2023 | acquisition | On April 20, 2022 | — |
KaVo Treatment Unit and Instrument Business (the "Divestiture")Word for word“As of December 31, 2022, all Deferred Local Closings were completed and we received total net cash consideration of $386.4 million in accordance with the terms of the Purchase Agreement.” 10-K for 2023 | divestiture | — | total net cash consideration of $386.4 million |
intraoral scanner businessWord for word“The acquisition of our intraoral scanner business in April 2022 added intraoral scanners and related software to our portfolio.” 10-K for 2025 | acquisition | April 2022 | — |
MatricelWord for word“Our Matricel and Osteogenics acquisitions added innovative regenerative solutions that are highly complementary to the implant treatment.” 10-K for 2025 | acquisition | — | — |
OsteogenicsWord for word“We intend to drive shareholder value by deploying capital to acquire or invest in other businesses that strategically fit into or extend our product offering into new or attractive adjacent markets; the Osteogenics acquisition in 2022 is an example of this strategy in action.” 10-K for 2025 | acquisition | 2022 | — |
Nobel BiocareWord for word“Since being acquired in 2014, Nobel Biocare has focused on reinvigorating its product offerings and has released over 30 new products.” 10-K for 2025 | acquisition | 2014 | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Cash received from selling businesses | Goodwill from acquisitions |
|---|---|---|---|
| 2018-12-31 | $0 | — | — |
| 2019-12-31 | $0 | $0 | — |
| 2020-12-31 | $40.7 million | $0 | — |
| 2021-12-31 | $2.1 million | $312.5 million | — |
| 2022-12-31 | $696.2 million | — | $450.4 million |
| 2023-12-31 | $0 | — | — |
| 2024-12-31 | $0 | — | — |
Deal filings since 2016
- 2023-09-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-08-11 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-12-22 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-09-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-06-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-02-10 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-05-26 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-05-11 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-09-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from Envista Holdings’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-12. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.